Anne Wojcicki’s Quest to Put People in Charge of Their Own Health
By Stephanie Lee,
San Francisco Chronicle
| 02. 28. 2015
[Quotes CGS's Marcy Darnovsky]
[The following is an excerpt. Access the full article here.]
Wojcicki (pronounced wo-JIT-ski) made it her mission to upend health care. In 2006, she co-founded 23andMe, a Silicon Valley company out to pool the world’s DNA, give individuals access to their genetics, and in the process transform the way drugs are made, diseases are cured and patients are treated. In that crowd is her husband, Google co-founder Sergey Brin, who learned from 23andMe that he has a genetic mutation putting him at high risk for Parkinson’s disease.
“To be able to answer thousands and thousands of questions,” she said, “you want tons and tons of data.”
So far, 23andMe has attracted nearly 1 million customers and more than $126 million in venture capital, making it one of the most hyped health-technology firms in the world — and its CEO one of the most influential women in tech.
But not everyone thinks Wojcicki should be the one to collect their data...
“They’ve had a very intense marketing campaign that’s made a lot of bold claims, both about the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...